Summary
Glucose-dependent insulinotropic polypeptide (GIP) is the second major incretin hormone, working alongside GLP-1 to link a meal to insulin secretion. It is released by intestinal K-cells and acts through the GIP receptor (GIPR) on pancreatic beta cells, fat tissue, and elsewhere. On its own GIP has a smaller reputation than GLP-1, but its combination with GLP-1 produces synergy that made the GIP/GLP-1 dual agonist tirzepatide one of the most studied metabolic peptides. This guide explains where GIP comes from, how its receptor signals, its roles in insulin and adipose tissue, and why hitting both incretin receptors together has become a central strategy in peptide science.
Key Takeaways
- GIP (glucose-dependent insulinotropic polypeptide) is an incretin — released after eating to amplify glucose-dependent insulin secretion.
- It is produced by intestinal K-cells, mostly in the upper small intestine, complementing GLP-1's lower-gut L-cells.
- The GIP receptor (GIPR) is a Gs-coupled GPCR that raises cyclic AMP (cAMP), like the GLP-1 receptor.
- GIP acts on pancreatic beta cells (insulin), and also on adipose tissue, where it influences fat metabolism and nutrient storage.
- Combining GIP and GLP-1 agonism produces effects greater than either alone — the rationale behind the dual agonist tirzepatide.
- Like GLP-1, native GIP is rapidly inactivated by the enzyme DPP-4, so long-acting analogs must be engineered for resistance.
- This is educational content only; incretin research peptides are sold for research use only, not for human consumption.
What GIP is and where it comes from
Glucose-dependent insulinotropic polypeptide (GIP) — historically also called gastric inhibitory polypeptide — is one of the two dominant incretin hormones. Incretins are gut hormones released after a meal that magnify insulin secretion beyond what glucose alone would trigger. Together, GIP and GLP-1 account for the majority of this so-called incretin effect, and in healthy physiology GIP is actually responsible for a large share of it.
GIP is secreted by enteroendocrine K-cells, which are concentrated in the upper small intestine (duodenum and jejunum). This is a useful contrast with GLP-1: GLP-1 comes from L-cells lower in the gut, so the two incretins are released from complementary regions as food moves through the digestive tract. K-cells respond especially to carbohydrates and fats, releasing GIP into the bloodstream to prime the pancreas for the incoming nutrient load.
Research-use-only, educational content
This article explains hormone biology for education. GIP-related research peptides and dual agonists discussed here — including tirzepatide and retatrutide — are sold for laboratory research use only, are not approved for human consumption in that form, and nothing here is medical advice.
The GIP receptor and how it signals
GIP works through the GIP receptor (GIPR), a class B G-protein-coupled receptor (GPCR) closely related to the GLP-1 and glucagon receptors. When GIP binds, GIPR couples to the Gs protein, activates adenylyl cyclase, and raises cyclic AMP (cAMP) inside the cell — the same second-messenger logic used across this receptor family. For the underlying mechanics, see understanding peptide receptors.
GIPR is expressed on pancreatic beta cells, but also notably in adipose (fat) tissue, bone, and the brain. This broader distribution — especially the adipose expression, which GLP-1R largely lacks — is a key reason GIP contributes something distinct to metabolism rather than simply duplicating GLP-1.
What GIP does in the body
GIP's best-established role is on the pancreas, but its actions in fat tissue are what make it scientifically interesting and, at times, debated.
| Feature | GIP | GLP-1 |
|---|---|---|
| Source cell | K-cells (upper intestine) | L-cells (lower intestine) |
| Insulin effect | Glucose-dependent, potent | Glucose-dependent, potent |
| Glucagon effect | Can raise glucagon | Suppresses glucagon |
| Adipose tissue | Direct effects on fat metabolism | Minimal direct effect |
| Appetite / gastric emptying | Weaker effect | Strong appetite and emptying effects |
On beta cells, GIP is a glucose-dependent insulin secretagogue — like GLP-1, it boosts insulin mainly when blood sugar is high, giving it a low intrinsic hypoglycemia risk. In adipose tissue, GIP influences nutrient uptake, lipid handling, and blood flow; its exact net effect on body weight has been an area of active investigation, which is part of why the role of GIPR agonism (versus antagonism) in metabolism has been studied from more than one angle.
Two incretins, complementary jobs
GIP and GLP-1 both drive glucose-dependent insulin release, but they diverge elsewhere: GLP-1 dominates appetite and gastric emptying, while GIP has distinctive actions in fat tissue. Their partial overlap plus partial divergence is exactly what makes combining them attractive.
DPP-4 and the short half-life
Like GLP-1, native GIP is a fleeting signal. The enzyme dipeptidyl peptidase-4 (DPP-4) clips GIP and inactivates it within minutes, after which the fragments are cleared by the kidneys. This makes the natural hormone impractical as a long-acting agent and means any GIP-based research peptide has to be engineered — through amino-acid substitutions and fatty-acid chains that promote albumin binding — to survive in circulation.
These are the same half-life-extension strategies used across the incretin field; the general principles are covered in the complete guide to peptide half-life. The upshot is that modern GIP-containing molecules can be studied on a weekly timescale even though native GIP lasts only minutes.
Why GIP + GLP-1 synergy matters
The reason GIP occupies so much research attention today is synergy with GLP-1. Because the two incretins share some actions (glucose-dependent insulin release) but differ in others (adipose effects, appetite, glucagon handling), engaging both receptors with a single molecule can produce metabolic effects greater than targeting either alone. This is the design behind tirzepatide, a GIP/GLP-1 dual agonist, and it is extended further in retatrutide, which adds glucagon-receptor activity for a triple agonist.
To see how these hormones combine, read the companion guides on GLP-1 biology and glucagon biology, and the overview of why one molecule that hits several receptors can outperform separate agents in the science of multi-agonist peptides. GIP is the piece that turned incretin therapy from single-target into multi-target science.
Frequently Asked Questions
What does GIP stand for?
GIP stands for glucose-dependent insulinotropic polypeptide (historically also called gastric inhibitory polypeptide). It is one of the two major incretin hormones, alongside GLP-1.
Where is GIP made?
GIP is produced by enteroendocrine K-cells, concentrated in the upper small intestine (duodenum and jejunum). This contrasts with GLP-1, which comes from L-cells in the lower gut.
How is GIP different from GLP-1?
Both are glucose-dependent incretins that boost insulin, but they diverge elsewhere: GLP-1 strongly suppresses glucagon, slows gastric emptying, and reduces appetite, while GIP has more prominent direct effects on adipose (fat) tissue and can raise glucagon.
What is the GIP receptor?
The GIP receptor (GIPR) is a class B G-protein-coupled receptor related to the GLP-1 and glucagon receptors. It couples to Gs, activates adenylyl cyclase, and raises cyclic AMP, and is expressed on beta cells, adipose tissue, bone, and brain.
Why is GIP combined with GLP-1 in tirzepatide?
Because the two incretins overlap in some actions and differ in others, engaging both receptors with one molecule can produce synergistic metabolic effects. Tirzepatide is a GIP/GLP-1 dual agonist built on this rationale.
Does native GIP last long in the body?
No. Native GIP is inactivated within minutes by the enzyme DPP-4 and then cleared by the kidneys, so long-acting GIP-based research peptides are engineered to resist degradation and bind albumin.
References
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology (review).Source
- Seino Y, Fukushima M, Yabe D. GIP and GLP-1: the two incretin hormones. Journal of Diabetes Investigation (review).Source
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism.Source
- National Center for Biotechnology Information (NCBI). GIP and GIP receptor (GIPR) gene/protein resources.Source
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism (review).Source
- U.S. National Library of Medicine, MedlinePlus. Insulin, incretins, and glucose regulation (background).Source
Research & Educational Use Only
This article is for general educational and informational purposes only and is not legal, medical, or regulatory advice. Laws and FDA policy change; verify the current status of any compound with primary FDA sources and a qualified professional before acting. Peptides discussed here are sold for research use only and are not intended for human consumption, diagnosis, treatment, or prevention of disease.